OpenAI launches GPT-Rosalind for life sciences workflows

21st April 2026

Summary: OpenAI has launched GPT-Rosalind, described as its first life sciences agent designed to support biology workflows across biochemistry, drug discovery and translational medicine. The model is intended to help researchers move more quickly through time-consuming scientific tasks and could help reduce delays between discovery and treatment. The announcement highlights the scale of the challenge, with drug approvals often taking 10 to 15 years, only around 10% of medicines passing US clinical trials, and more than 300 million people worldwide living with rare diseases. OpenAI says Rosalind is meant to support, not replace, scientific expertise, and notes that no fully AI-designed drug has yet passed Phase 3 clinical trials. The rollout is being limited through a trusted access programme for carefully vetted organisations, in response to safety concerns raised by experts about the misuse of biological data. Early partners include Amgen, Moderna, Thermo Fisher Scientific and the Allen Institute.

Back to Recent News